Impact of factor VIII deficiency on clotting factor utilization in the United States.
In a study of 1,551 hemophiliacs over a 4-year period of time, factor VIII utilization was assessed. It is clear that factor VIII usage is a function of severity of disease and therapeutic program. The average amount of factor VIII used per patient was 39,880 U/year. Patients selected for home care, use significantly more than those patients not on home care. As much as 101,000 U/year are used by a small number of patients on prophylaxis. These data can be used in predicting source plasma requirements for annual national use as well as costs.
D001782:Blood Donors; D003450:Cryoglobulins / Q000627:therapeutic use*; D005169:Factor VIII / Q000008:administration & dosage*; D006467:Hemophilia A / Q000191:economics / Q000628:therapy*; D006701:Home Nursing; D006801:Humans; D010956:Plasmapheresis / Q000191:economics*; D011446:Prospective Studies; D013514:Surgical Procedures, Operative; D014481:United States
D003450:Cryoglobulins; D005169:Factor VIII